Trading Report: Today, Robert W. Baird Downgrade Nivalis Therapeutics Inc. (NVLS) to Neutral

Today, Robert W. Baird Downgrade Nivalis Therapeutics Inc. (NVLS) to Neutral

Nivalis Therapeutics Inc. (NASDAQ:NVLS) was downgraded by research analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a research note issued on Tuesday. They presently have a $3.00 price target on the stock, down from their previous price target of $29.00. Robert W. Baird’s price objective indicates a potential downside of 52.00% from the company’s current price.

Several other equities research analysts have also commented on NVLS. Raymond James Financial Inc. started coverage on shares of Nivalis Therapeutics in a research note on Tuesday, September 13th. They set an “outperform” rating and a $20.00 price target on the stock. Piper Jaffray Cos. reiterated a “buy” rating and set a $16.00 price target on shares of Nivalis Therapeutics in a research note on Tuesday, August 30th. HC Wainwright reiterated a “buy” rating on shares of Nivalis Therapeutics in a research note on Monday, August 8th. Zacks Investment Research upgraded shares of Nivalis Therapeutics from a “sell” rating to a “buy” rating and set a $8.50 price target on the stock in a research note on Thursday, October 20th. Finally, Cowen and Company reiterated a “buy” rating on shares of Nivalis Therapeutics in a research note on Monday, August 1st. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Nivalis Therapeutics has an average rating of “Buy” and an average price target of $9.60.

Shares of Nivalis Therapeutics (NASDAQ:NVLS) opened at 6.25 on Tuesday. The stock’s 50 day moving average is $6.46 and its 200-day moving average is $5.84. Nivalis Therapeutics has a one year low of $3.68 and a one year high of $9.45. The stock’s market capitalization is $97.14 million.

Nivalis Therapeutics (NASDAQ:NVLS) last issued its quarterly earnings results on Monday, November 7th. The company reported ($0.48) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.11. On average, equities research analysts predict that Nivalis Therapeutics will post ($2.10) EPS for the current fiscal year.

In other news, EVP David Malcom Rodman sold 5,820 shares of Nivalis Therapeutics stock in a transaction dated Tuesday, October 4th. The shares were sold at an average price of $7.96, for a total value of $46,327.20. Following the sale, the executive vice president now owns 18,056 shares of the company’s stock, valued at $143,725.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.00% of the stock is currently owned by insiders.

Several hedge funds have recently modified their holdings of the stock. Paloma Partners Management Co bought a new stake in Nivalis Therapeutics during the second quarter worth approximately $105,000. Bank of New York Mellon Corp increased its stake in Nivalis Therapeutics by 7.8% in the third quarter. Bank of New York Mellon Corp now owns 16,494 shares of the company’s stock worth $134,000 after buying an additional 1,189 shares in the last quarter. Spark Investment Management LLC bought a new stake in Nivalis Therapeutics during the third quarter worth approximately $145,000. Endurant Capital Management LP increased its stake in Nivalis Therapeutics by 29.8% in the third quarter. Endurant Capital Management LP now owns 85,412 shares of the company’s stock worth $694,000 after buying an additional 19,629 shares in the last quarter. Finally, Opaleye Management Inc. increased its stake in Nivalis Therapeutics by 160.0% in the second quarter. Opaleye Management Inc. now owns 260,000 shares of the company’s stock worth $1,287,000 after buying an additional 160,000 shares in the last quarter. 79.26% of the stock is currently owned by institutional investors and hedge funds.

Nivalis Therapeutics Company Profile

Related posts

Leave a Comment